Topic: Profiles of Environmental Toxins and HCC Risk Mitigation Strategies
A Special Issue of Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)
Submission deadline: 15 Nov 2024
Guest Editor(s)
Special Issue Introduction
Liver cancer is the second most frequent gastrointestinal cancer for mortality. The most common type of primary liver cancer is hepatocellular carcinoma (HCC), accounting for almost 90% of cases. In particular, HCC is the fourth leading cause of cancer-related death, with a five-year survival rate of only 20% for patients with advanced liver disease.
HCC pathophysiology involves several etiopathogenetic factors: lifestyle (such as eating and drinking habits), viral infections, drug-induced liver damage, metabolic-associated steatosis liver disease (MASLD), immune system derangement, and primary liver diseases. Recently, exposure to environmental toxins (e.g., widespread pesticide use, aflatoxin-contaminated foods, and harmful cyanobacterial algae) has become a significant concern in liver disease and HCC outbreaks. Mounting evidence suggests that environmental toxins may represent an important contributing factor in the development of hepatocellular carcinoma.
This Special Issue aims to provide a platform for authors to discuss the key environmental toxins leading to HCC development worldwide. Authors will present high-quality information on the latest evidence regarding how various lifestyle behaviors, including excessive alcohol consumption and exposure to food toxins, impact liver health. Additionally, this issue will explore the evolving concept of MASLD and its relevance to HCC development. We will also focus on the role of gut microbiota in the entry and processing of environmental toxins in the liver. Modulating the gut microbiota presents a promising approach for preventing and treating HCC related to environmental toxin exposure. Furthermore, authors are encouraged to report on recent pharmacological strategies for reversing and treating hepatocarcinogenesis. Finally, considering viruses as microbiologically relevant acquired “liver toxins”, the issue will include discussions on the impact of the SARS-CoV 2 pandemic on the diffusion and dynamics of environmental toxins and the pathophysiology of liver carcinogenesis.
Potential topics include, but are not limited to, the following:
1. Aflatoxins and liver disease until carcinogenesis;
2. Drug-derived liver toxins in HCC;
3. Alcohol as recreational and addiction toxin in liver cancer development;
4. Environmental toxins and MASLD progression to HCC;
5. Microbial toxins and liver carcinogenesis;
6. Food toxins and liver cancer;
7. Pharmacological remedies for hepatotoxins in HCC;
8. Gut microbiota as liver toxicity modulator in HCC;
9. Probiotics and hepatotoxic toxins: a promising interaction in HCC patients;
10. Novel scavengers for environmental liver toxicity treatment in HCC process;
11. Perspectives on liver toxins and environmental pollution in HCC process;
12. SARS-CoV 2 pandemic and liver toxins in HCC development.
HCC pathophysiology involves several etiopathogenetic factors: lifestyle (such as eating and drinking habits), viral infections, drug-induced liver damage, metabolic-associated steatosis liver disease (MASLD), immune system derangement, and primary liver diseases. Recently, exposure to environmental toxins (e.g., widespread pesticide use, aflatoxin-contaminated foods, and harmful cyanobacterial algae) has become a significant concern in liver disease and HCC outbreaks. Mounting evidence suggests that environmental toxins may represent an important contributing factor in the development of hepatocellular carcinoma.
This Special Issue aims to provide a platform for authors to discuss the key environmental toxins leading to HCC development worldwide. Authors will present high-quality information on the latest evidence regarding how various lifestyle behaviors, including excessive alcohol consumption and exposure to food toxins, impact liver health. Additionally, this issue will explore the evolving concept of MASLD and its relevance to HCC development. We will also focus on the role of gut microbiota in the entry and processing of environmental toxins in the liver. Modulating the gut microbiota presents a promising approach for preventing and treating HCC related to environmental toxin exposure. Furthermore, authors are encouraged to report on recent pharmacological strategies for reversing and treating hepatocarcinogenesis. Finally, considering viruses as microbiologically relevant acquired “liver toxins”, the issue will include discussions on the impact of the SARS-CoV 2 pandemic on the diffusion and dynamics of environmental toxins and the pathophysiology of liver carcinogenesis.
Potential topics include, but are not limited to, the following:
1. Aflatoxins and liver disease until carcinogenesis;
2. Drug-derived liver toxins in HCC;
3. Alcohol as recreational and addiction toxin in liver cancer development;
4. Environmental toxins and MASLD progression to HCC;
5. Microbial toxins and liver carcinogenesis;
6. Food toxins and liver cancer;
7. Pharmacological remedies for hepatotoxins in HCC;
8. Gut microbiota as liver toxicity modulator in HCC;
9. Probiotics and hepatotoxic toxins: a promising interaction in HCC patients;
10. Novel scavengers for environmental liver toxicity treatment in HCC process;
11. Perspectives on liver toxins and environmental pollution in HCC process;
12. SARS-CoV 2 pandemic and liver toxins in HCC development.
Submission Deadline
15 Nov 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr2408053
Submission Deadline: 15 Nov 2024
Contacts: Ada Zhong, Assistant Editor, editor_ada@hrjournal.net
